Anti‐CTLA‐4 monotherapy was associated with longer OS for patients with melanoma, whereas anti‐PD‐L1 + anti‐CLTA‐4 combination therapy were associated with longer OS for NSCLC and RCC. Here, CTLA4 is linked to melanoma.